Diabetic macular oedema (DME) represents the most common cause of vision loss in patients affected by diabetes mellitus. Diabetic retinopathy has a significant impact on public health and the quality of life of many patients and thus requires serious consideration. The first line of treatment remains the management of systemic risk factors but this is often insufficient in controlling DME and currently, laser retinal photocoagulation is considered the standard of care. However, laser treatment reduces the risk of moderate visual loss by approximately 50 % without guaranteeing remarkable effects on visual improvement. For these reasons, new approaches in the treatment of DME have been considered, in particular the employment of anti-vascular endothelial growth factor (VEGF) drugs. VEGF is a pluripotent growth factor that functions as a vasopermeability factor and an endothelial cell mitogen and thereby represents an appealing candidate as a therapeutic target for the treatment of DME. The goal of this article is to present the evidence behind the use of anti-VEGF drugs in the treatment of DME.
Today, diabetic retinopathy is the leading cause of acquired blindness among young adults throughout developed countries. 2 Population-based epidemiological studies have estimated that, after 20 years, diabetic retinopathy can be identified at least to a certain extent and that, after 30 years, proliferative diabetic retinopathy is present in 70 % of patients with diabetes mellitus type 1. 3 The World
Health Organization (WHO) estimates that about 171 million people are affected by diabetes with a likely doubling of the prevalence within 20 years. 4 Diabetic macular oedema (DME) is the major cause of visual acuity (VA) impairment secondary to diabetic retinopathy. DME is generally defined as retinal thickening or presence of hard exudates within one disk diameter from the centre of the macula. 5 During past years, many therapeutic strategies have been proposed for the treatment of DME including focal/grid laser photocoagulation, ocular steroids, intravitreal anti-vascular endothelial growth factor (VEGF) drugs and vitreo-retinal surgery. VEGF is a pluripotent growth factor that acts as an endothelial cell-specific mitogen and vasopermeability factor, playing a critical role in promoting angiogenesis and vascular leakage. [6] [7] [8] [9] [10] In diabetic retinopathy, the alteration of the blood-retinal barrier and increased permeability are responsible for the development of DME. VEGF increases the extracellular accumulation of fluid from the intravascular compartment by disrupting the intercellular tight junctions between retinal endothelial cells. [8] [9] [10] [11] The pathway between VEGF gene transcription and 
Ranibizumab
Ranibizumab is an antigen-binding fragment (Fab) derived from a humanised anti-VEGF antibody that inhibits all biologically active isoforms and active proteolytic fragments of VEGF-A. Many clinical investigations have shown its efficacy in the treatment of DME.
In the first pilot study, two dosing regimens of ranibizumab (0.3 and 0.5 mg) were used in 10 patients affected by clinically significant DME. 12 At month three, 40 % of patients gained more than 15 letters, 50 % gained more than 10 letters, and 80 % obtained an improvement of at least one letter in best corrected visual acuity (BCVA) and a decrease in central retinal thickness (CRT) was detected in both groups. open-label study Ranibizumab for oedema of the macula in diabetes:
Phase I (READ-1). 13 Ten patients with chronic DME received intraocular injections of 0.5 mg ranibizumab at baseline and at one, two, four and six months. Mean and median values of BCVA improved at seven months by 12.3 and 11 letters, respectively, and foveal thickness showed a significant reduction.
Recently, the results of the second phase of the READ study 14, 15 (READ-2, a phase II, prospective, randomised clinical trial conducted at 14 sites in the US) were reported. The aim of this study was to compare ranibizumab with focal/grid laser, alone or in combination.
One hundred and twenty-six patients were randomised to receive 0.5 mg ranibizumab (group 1, n=42), focal/grid laser photocoagulation (group 2, n=42) or a combination of 0.5 mg ranibizumab and focal/grid laser (group 3, n=42). Baseline characteristics were well balanced in the randomisation groups. Subjects with BCVA between 20/40 and 20/320 due to DME and CRT of 250 μm or more were recruited.
Patients in the ranibizumab group received an injection at baseline and months one three and five. Patients in the laser group received focal or grid laser photocoagulation at baseline and again at month three if central subfield thickness (CST) was 250 μm or more. At baseline and month three, patients in the combined therapy group received an intraocular injection of ranibizumab followed by focal or grid laser treatment one week later.
At month six, the group receiving ranibizumab alone showed a significant improvement in mean BCVA compared with patients receiving focal/grid laser. BCVA in the group receiving combined therapy was not statistically different from the other groups.
A resolution of 50, 33, and 45 % of excess foveal thickening was observed, respectively, in the three groups after six months. After the primary endpoint (six months), patients in all groups were seen every two months, and if they had persistent or recurrent DME, defined as CRT of 250 μm or more, patients in group 1 could receive an intraocular injection of 0.5 mg, patients in group 2 ranibizumab alone or laser, and patients in group 3 ranibizumab alone or combined with laser. The two-year outcomes of READ-2 showed an improvement in BCVA of 7.7, 5.1 and 6.8 letters compared with baseline in groups 1, 2 and 3, respectively. CRT at month 24 was 340, 286 and 258 μm for groups 1, 2 and 3, respectively, and the percentages of patients with CRT of 250 μm or less were 36, 47 and 68 %. The mean number of injections was 5.3, 4.4 and 2.9 in the respective groups. Twenty-eight patients were left the study before the two-year endpoint: 10 in group 1, eight in group 2 and 10 in group 3.
The study reported a single case of severe adverse event: one subject died of a cerebrovascular accident six weeks after the first ranibizumab injection. This event was considered unrelated to ranibizumab because of pre-existent cardiovascular pathology and because a long period elapsed between injection and vascular event.
No statistically significant differences in mean systolic and diastolic blood pressure were found between the groups. Ocular adverse events included vitreous haemorrhages in eight patients. The visual outcomes of the READ-2 study at month 24 were not significantly different in the three treatment groups, whereas the anatomical outcomes were better, with fewer injections of ranibizumab in groups 2 and 3. This suggests that the additional focal/grid laser treatment in groups 2 and 3 helped to reduce persistent or recurrent macular oedema as well as the number of ranibizumab injections required. sham arms, respectively. However, the effect of laser on BCVA was not evaluated. In conclusion, the study confirmed the efficacy of ranibizumab in improving BCVA in patients with DME.
The Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema (RESTORE) study, At one year of follow-up, no significant differences were detected between ranibizumab monotherapy and ranibizumab associated with laser photocoagulation. In the RESTORE study 18 no cases of endophthalmitis were reported. Increased intraocular pressure was reported for one patient each in the ranibizumab arms. No increased risk of cardiovascular or cerebrovascular events was documented in this study. Overall, the RESTORE study demonstrates that ranibizumab monotherapy provides superior outcomes compared
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with standard-of-care treatment in patients with visual impairment due to DME. Long-term results are awaited to evaluate the outcomes of laser treatment alone and in combination with ranibizumab. The study has a limited follow-up to allow a real efficacy comparison with laser treatment, the latter being slower in producing its effects.
It is well known that corticosteroids play an important role in reducing DME 19, 20 This trial confirms the promising preliminary results in the treatment of DME, suggesting that a combined therapy might offer a more efficient approach considering the multifactorial pathogenesis of the disorder. Moreover, it is once again demonstrated that laser treatment requires many months to become active on DME. Recently, the results of a sham-controlled, multicentre, parallel-group study were reported. 25 The aim of this study was to demonstrate the efficacy of 0. 
Bevacizumab
Bevacizumab is a full-length recombinant humanised antibody active against all isoforms of VEGF. Short-term effects of bevacizumab for Diabetic Macular Oedema
DME in a large randomised Phase II clinical trial were initially reported by the DRCRnet. 26 One hundred nine subjects with DME and Snellen acuity equivalent ranging from 20/32 to 20/320 were prospectively enrolled and randomised to five groups:
• focal photocoagulation at baseline;
• intravitreal injection of 1.25 mg bevacizumab at baseline and six weeks;
• intravitreal injection of 2.5 mg bevacizumab at baseline and six weeks;
• intravitreal injection of 1.25 mg bevacizumab at baseline and sham injection at six weeks; or
• intravitreal injection of 1.25 mg bevacizumab at baseline and six weeks with photocoagulation at three weeks.
The BCVA in the groups receiving bevacizumab alone showed a median one-line improvement at the three-week visit, which was preserved up to 12 weeks and was greater than the change in the group receiving only focal photocoagulation at baseline. A similar Long-term efficacy of repeated injections of intravitreal bevacizumab 1.25 mg for the treatment of chronic DME was also reported by Kook et al. 29 The study (prospective, consecutive, non-comparative case series) included 126 patients affected by chronic, diffuse, clinically significant DME in part not responsive to previous treatments. difference. This study showed that, even in cases with chronic diffuse ischaemic DME not responding to other therapy, a successful treatment with repeated intravitreal injections of bevacizumab can be achieved over a long-term follow-up period.
Other studies compared intravitreal bevacizumab treatment with intravitreal triamcinolone or focal retinal photocoagulation in refractory DME or as primary treatment. Paccola et al. designed a randomised, prospective study in order to evaluate the anatomical response and VA outcomes after a single intravitreal injection of triamcinolone acetonide (4 mg) or bevacizumab (1.25 mg) in refractory diffuse DME. 30 The study enrolled 26 patients; at baseline, the logMAR BCVA was 0.936 and 0.937 in the triamcinolone and bevacizumab groups, respectively. At six months, the BCVA improved to 0.91 and 0.92 without achieving a significant difference; however, interim analysis at one-, two-and three-month examinations evidenced a significant improvement in the triamcinolone group compared with the bevacizumab group.
A similar prospective and comparative case series was reported by Shimura et al. 31 The study recruited 14 patients with bilateral long-standing DME; in each patient, one eye was selected to receive a single intravitreal injection of triamcinolone (4 mg A randomised, three-arm clinical trial comparing intravitreal bevacizumab injection (1.25 mg, n=50), alone or in combination with intravitreal triamcinolone acetonide (2 mg, n=50), versus macular laser photocoagulation (n=50) as a primary treatment of DME was published by Soheilian et al. 32 The bevacizumab group showed a significant BCVA improvement, from 0.71 to 0.54 at six weeks; the initial gain was 
improvement in the bevacizumab group was significantly greater than in the other groups. With a longer follow-up, however, bevacizumab turned out to be superior to bevacizumab/triamcinolone and macular laser photocoagulation only in the eyes with initial CMT of ≥350 μm, indicating that in the primary treatment of DME, initial CMT may be an important factor in decision-making.
Recently, the results of a retrospective, multicentre, interventional comparative case series involving 115 consecutive patients (139 eyes)
with DME receiving primary treatment with 1.25 or 2.5 mg bevacizumab were published. 34 Patients received re-injections whenever there was a recurrence of DME (defined by a decrease in BCVA associated with the presence of intraretinal fluid on OCT or fluorescein angiography). In the first month after the initial bevacizumab injection, improvements in BCVA and CMT measurements were recorded and these significant changes continued throughout the 24-month follow-up. BCVA analysis at 24 months showed that 62 (44.6 %) eyes remained stable, 72 (51.8 %)
eyes improved by two or more ETDRS lines and five (3.6 %) eyes decreased by two or more ETDRS lines.
The one-year results of a prospective randomised trial were recently reported. 35 The Bevacizumab or laser therapy in the management of diabetic macular edema (BOLT) study recruited 80 patients (80 eyes)
affected by centre-involving clinically significant DME and at least one previous macular laser treatment. Subjects were randomised to two and -67 in the bevacizumab and laser groups, respectively (p=0.06).
The median number of treatments was nine in the bevacizumab arm and three in the laser treatment arm. The findings of this study support the use of bevacizumab for DME. However, to confirm these results a larger trial with a longer follow-up period and a treatment arm that includes laser + bevacizumab therapy is needed. have been shown to determine excessive vascular permeability. This higher affinity will most probably allow lower doses to be employed and a longer duration of action to be maintained. 37, 38 A Phase I study exploring the safety and bioactivity of a single injection of 4.0 mg VEGF Trap-Eye in subjects with DME demonstrated a reduction in CRT and significant improvement in VA. 39 In a recent study, 221 diabetic patients with DME were enrolled and assigned to five different groups characterised by different dosing regimens of intravitreal VEGF Trap (monthly injection of 0.5 or 2 mg VEGF Trap, three monthly injections followed by other injections every eight weeks or on PRN regimen, or macular laser photocoagulation alone). 40 The from this trial suggest that subconjunctival rapamycin is safe in the treatment of patients with DME; however, conclusions cannot be drawn regarding its therapeutic efficacy in DME, since the findings could also be attributed to the natural history of DME or laser treatment. In order to demonstrate the possible therapeutic effect of rapamycin a large randomised clinical trial must be designed.
Vascular Endothelial Growth Factor Trap

Conclusions
VEGF plays a key role in promoting angiogenesis and vascular leakage and today represents an attractive candidate as a therapeutic target in the treatment and management of diabetic retinopathy. The advent of intravitreal anti-VEGF drugs has opened a new era for the management of DME. While focal/grid laser remains a standard treatment for DME and is supported by evidence provided by large-scale studies, 51 Evidence for Anti-vascular Endothelial Growth Factor Treatment of Diabetic Macular Oedema
